Abstract
Background:Definitive chemoradiotherapy (dCRT) is widely considered as a treatment option for cervical esophageal squamous cell carcinoma (ESCC) toward preserving the larynx. We have reported favorable outcomes, including the treatment response rate and short-term survival of dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for advanced cervical ESCC. The aim of this paper was to report the subsequent progress of the study. Methods:We assessed 18 patients with advanced (clinical stage II–IV, including T4b and/or M1 lymph node) cervical ESCC at our department who received DCF-RT as the first-line treatment between December 2010 and June 2020. Results:A total of 14 men and 4 women underwent the study regimen. The pretreatment clinical stage included stage II, stage III, stage IVA, and stage IVB cases (including 9 patients with T4b) [8 trachea and 2 thyroids] and 7 patients with the M1 lymph node. The complete response (CR) was achieved in 15 patients, stable disease in 2, and progressive disease in 1. Of 15 patients with CR, 7 experienced recurrence, and 8 had continued CR. Frequent cases of grade ≥3 adverse effects included leucopenia, neutropenia, febrile neutropenia, and pharyngeal pain. The 3-year overall survival rate, disease-free survival rate, and disease-specific survival rate were 44.2%, 47.7%, and 48.6%, respectively. Conclusion:DCF-RT for advanced cervical esophageal cancer could achieve a favorable prognosis with larynx preservation. Further observations are warranted to establish the long-term prognosis, late complications of radiotherapy, and the significance of salvage surgery.
Highlights
Esophageal cancer is one of the common types of cancer across the world, among which the prevalence of cervical esophageal carcinoma (4.8%) is lesser than that of thoracic esophageal carcinoma (Watanabe et al, 2021)
We have reported favorable outcomes, including the treatment response rate and short-term survival of Definitive chemoradiotherapy (dCRT) concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for advanced cervical esophageal squamous cell carcinoma (ESCC)
The use of definitive chemoradiotherapy is the preferred choice of treatment for cervical esophageal squamous cell carcinoma (ESCC) that has been shown to preserve the progression of disease in the larynx
Summary
Esophageal cancer is one of the common types of cancer across the world, among which the prevalence of cervical esophageal carcinoma (4.8%) is lesser than that of thoracic esophageal carcinoma (Watanabe et al, 2021). The use of definitive chemoradiotherapy (dCRT) is the preferred choice of treatment for cervical esophageal squamous cell carcinoma (ESCC) that has been shown to preserve the progression of disease in the larynx. The treatment response rate and the short-term survival of dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for advanced cervical ESCC were evaluated for the first time (Okamoto et al, 2018). We report the subsequent progress of our previous study using DCF-RT for advanced cervical ESCC. We have reported favorable outcomes, including the treatment response rate and short-term survival of dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for advanced cervical ESCC. Methods: We assessed 18 patients with advanced (clinical stage II–IV, including T4b and/or M1 lymph node) cervical ESCC at our department who received DCF-RT as the first-line treatment between December 2010 and June 2020. Further observations are warranted to establish the long-term prognosis, late complications of radiotherapy, and the significance of salvage surgery
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
